Magnesium therapy, fibrinolytic parameters and von Willebrand factor in acute myocardial infarction

Int J Cardiol. 1996 Sep;56(1):53-9.

Abstract

Sixty-one patients with non-thrombolytic treated acute myocardial infarction were randomised to open magnesium infusion or control. tPA activity, tPA mass, PAI-1 mass and von Willebrand factor (vWF) were measured in blood samples drawn at entrance and after on average 10 h and 18 h following inclusion in the trial. No differences for the hemostatic variables assay type were detected between the two groups. Fluctuations in the fibrinolytic parameters were maintained in the magnesium group, but blunted in the control group regarding PAI-mass and tPA-activity. This study gives no evidence that magnesium infusion in acute myocardial infarction influences fibrinolytic parameters or vWF.

Publication types

  • Clinical Trial
  • Controlled Clinical Trial
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Enzyme-Linked Immunosorbent Assay
  • Female
  • Fibrinolysis / physiology*
  • Humans
  • Infusions, Intravenous
  • Magnesium Sulfate / administration & dosage
  • Magnesium Sulfate / therapeutic use*
  • Male
  • Myocardial Infarction / blood
  • Myocardial Infarction / drug therapy*
  • Myocardial Infarction / physiopathology
  • Plasminogen Activator Inhibitor 1 / blood
  • Platelet Aggregation / drug effects
  • Retrospective Studies
  • Tissue Plasminogen Activator / blood
  • Vectorcardiography
  • von Willebrand Factor / drug effects
  • von Willebrand Factor / metabolism*

Substances

  • Plasminogen Activator Inhibitor 1
  • von Willebrand Factor
  • Magnesium Sulfate
  • Tissue Plasminogen Activator